Les Références



(1) Sculier JP, Berghmans T, Paesmans M, Branle F, Lemaitre F, Mascaux C et al. La place de la chimiothérapie dans le traitement des cancers bronchiques non à petites cellules non métastatiques. Rev Med Brux 2001; 22(6):477-487.
(2) Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001; 1(1):5.
(3) Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30(1):23-36.
(4) Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Sculier JP. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002; 37(2):115-123.
(5) Grol R, Cluzeau FA, Burgers JS. Clinical practice guidelines: towards better quality guidelines and increased international collaboration. Br J Cancer 2003; 89 Suppl 1:S4-S8.
(6) Burgers JS, Fervers B, Haugh M, Brouwers M, Browman G, Philip T et al. International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol 2004; 22(10):2000-2007.
(7) Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12(1):18-23.
(8) Guideline development in Europe. An international comparison. Int J Technol Assess Health Care 2000; 16(4):1039-1049.
(9) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15(8):2996-3018.
(10) Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22(2):330-353.
(11) BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56(2):89-108.
(12) Levine M, Browman G, Newman T, Cowan DH. The Ontario Cancer Treatment Practice Guidelines Initiative. Oncology (Huntingt) 1996; 10(11 Suppl):19-22.
(13) The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer. Clin Oncol (R Coll Radiol) 1999; 11(1):S1-S53.
(14) Alberts WM. Lung Cancer Guidelines. Introduction. Chest 2003; 123:1S-2S.
(15) Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E et al. Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000). Br J Cancer 2003; 89 Suppl 1:S35-S49.
(16) McCrory DC, Colice GL, Lewis SZ, Alberts WM, Parker S. Overview of methodology for lung cancer evidence review and guideline development. Chest 2003; 123(1 Suppl):3S-6S.
(17) Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E et al. Standards, Options et Recommendations 2000 pour la prise en charge des patients atteints d'un cancer bronchopulmonaire non à petites cellules (rapport abrégé). Br J Cancer 2003; 89 Suppl 1:S35-S49.
(18) Smythe WR. Treatment of stage I non-small cell lung carcinoma. Chest 2003; 123(1 Suppl):181S-187S.
(19) Scott WJ, Howington J, Movsas B. Treatment of stage II non-small cell lung cancer. Chest 2003; 123(1 Suppl):188S-201S.
(20) Robinson LA, Wagner H, Jr., Ruckdeschel JC. Treatment of stage IIIA non-small cell lung cancer. Chest 2003; 123(1 Suppl):202S-220S.
(21) Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003; 123(1 Suppl):221S-225S.
(22) Warren WH. Historical facets of thoracic surgery emphasizing lung cancer. In: Gruhn JG, Rosen ST, editors. Lung Cancer. The evolution of concepts. Volume II. New York: Field & Wood, 1989: 73-106.
(23) Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111(6):1710-1717.
(24) Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60(3):615-622.
(25) Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer. World J Surg 2000; 24(1):27-30.
(26) Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg 2003; 76(6):1782-1788.
(27) Mathur PN, Edell E, Sutedja T, Vergnon JM. Treatment of early stage non-small cell lung cancer. Chest 2003; 123(1 Suppl):176S-180S.
(28) Touboul E, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E et al. Standards, Options et Recommandations pour la prise en charge des patients atteints d'un cancer bronchique primitif de stade I ou II traités par irradiation exlusive. Cancer Radiother 2001; 5(4):452-463.
(29) Izbicki JR, Thetter O, Habekost M, Karg O, Passlick B, Kubuschok B et al. Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial. Br J Surg 1994; 81(2):229-235.
(30) Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR. Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg 2002; 21(3):520-526.
(31) Wu Y, Huang Z, Wang S, Yang X, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer 2002; 36(1):1-6.
(32) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352(9124):257-263.
(33) Burdett S, Stewart L. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 2005; 47(1):81-83.
(34) Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B et al. Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung Cancer. J Clin Oncol 2002; 20(1):247-253.
(35) Niiranen A, Niitamo-Korhonen S, Kouri M, Assendelft A, Mattson K, Pyrhonen S. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol 1992; 10(12):1927-1932.
(36) Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst 1993; 85(4):299-306.
(37) Wada H, Miyahara R, Tanaka F, Hitomi S. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 1999; 15(4):438-443.
(38) Mineo TC, Ambrogi V, Corsaro V, Roselli M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg 2001; 20(2):378-384.
(39) Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, Kawamura M et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003; 40(2):181-186.
(40) Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350(17):1713-1721. (
41) Strauss GM, Maddaus MA, Johnson EA, Sugarbaker DG, Hemdon JEI, Johnstone DW et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection of stage IB NSCLC. Report of CALGB protocol 9633. Proc Amer Soc Clin Oncol 23. 2004.
(42) Winton T, Livingston R, Johnson D, Rigas J, Cormier Y, Butts C et al. Phase III randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non small cell lung cancer. Proc Amer Soc Clin Oncol 23. 2004.
(43) Dautzenberg B, Chastang C, Arriagada R, Le Chevalier T, Belpomme D, Hurdebourcq M et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer 1995; 76(5):779-786.
(44) A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur J Surg Oncol 1995; 21(1):69-77.
(45) Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95(19):1453-1461.
(46) Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350(4):351-360.
(47) Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311(7010):899-909.
(48) Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22(19):3860-3867.
(49) Sedrakyan A, Van Der MJ, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004; 128(3):414-419.
(50) Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan Clinical Oncology Group. J Thorac Cardiovasc Surg 1993; 106(4):703-708.
(51) Tada H, Tsuchiya R, Ichinose Y, Koike T, Nishizawa N, Nagai K et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004; 43(2):167-173.
(52) Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ et al. A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non-Small-Cell Lung Cancer. N Engl J Med 2000; 343(17):1217-1222.
(53) Detterbeck FC, Jones DR, Kernstine KH, Naunheim KS. Lung cancer. Special treatment issues. Chest 2003; 123(1 Suppl):244S-258S.
(54) Johnstone DW, Byhardt RW, Ettinger D, Scott CB. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54(2):365-369.
(55) Albain KS, Scott CB, Rusch V, Turrisi A, III, Shepherd F, Smith G et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIA (pN2) non-small cell lung cancer. Initial results from Intergroup trial 0139 (RTOG 93-09). Proc Amer Soc Clin Oncol 22, 621. 2003.
(56) Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992; 53(6):992-998.
(57) Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330(3):153-158.
(58) Rosell R, Gomez-Codina J, Camps C, Javier SJ, Maestre J, Padilla J et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26(1):7-14.
(59) Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JBJ, Lee JS et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86(9):673-680.
(60) Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette RM, Putnam JBJ et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21(1):1-6.
(61) Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 125(2):254-260.
(62) Lad T. The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled paratracheal node (stage IIIA). LCSG 791. Chest 1994; 106(6 Suppl):302S-306S. (63) Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292(4):470-484.

retour à index